BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical (BMRN) Stock Price & Analysis


BMRN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$70.73 - $117.77
Previous Close$91.44
Average Volume (3M)1.55M
Market Cap
Enterprise Value$16.87B
Total Cash (Recent Filing)$1.29B
Total Debt (Recent Filing)$1.09B
Price to Earnings (P/E)125.2
Apr 26, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.73
Shares Outstanding186,528,784
10 Day Avg. Volume1,535,783
30 Day Avg. Volume1,545,102
Standard Deviation0.09
Financial Highlights & Ratios
Price to Book (P/B)4.16
Price to Sales (P/S)8.07
Price to Cash Flow (P/CF)97.50
P/FCF Ratio381.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.05
Enterprise Value/Gross Profit10.46
Enterprise Value/Ebitda63.20
Price Target Upside29.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was $70.73 and its highest was $117.77 in the past 12 months.
    What is BioMarin Pharmaceutical’s market cap?
    Currently, no data Available
    When is BioMarin Pharmaceutical’s upcoming earnings report date?
    BioMarin Pharmaceutical’s upcoming earnings report date is Apr 26, 2023 which is in 28 days.
      How were BioMarin Pharmaceutical’s earnings last quarter?
      BioMarin Pharmaceutical released its earnings results on Feb 27, 2023. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.058 by $0.058.
        Is BioMarin Pharmaceutical overvalued?
        According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does BioMarin Pharmaceutical pay dividends?
          BioMarin Pharmaceutical does not currently pay dividends.
          What is BioMarin Pharmaceutical’s EPS estimate?
          BioMarin Pharmaceutical’s EPS estimate is $0.15.
            How many shares outstanding does BioMarin Pharmaceutical have?
            BioMarin Pharmaceutical has 186,528,780 shares outstanding.
              What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
              BioMarin Pharmaceutical reported an EPS of $0 in its last earnings report, beating expectations of -$0.058. Following the earnings report the stock price went down -3.535%.
                Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
                Among the largest hedge funds holding BioMarin Pharmaceutical’s share is PRIMECAP Management Co. It holds BioMarin Pharmaceutical’s shares valued at 2B.


                  BioMarin Pharmaceutical Stock Smart Score

                  The BioMarin Pharmaceutical stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  BioMarin Pharmaceutical

                  BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.


                  Top 5 ETFs holding BMRN

                  Market Value
                  Smart Score
                  Lyxor MSCI World (LUX) UCITS ETF
                  VanEck Biotech ETF
                  Ly FTSE 100 ETF Act. -Montly Hedged C USD-
                  Lyxor FTSE China A50 UCITS ETF
                  Desjardins SocieTerra American Equity ETF Trust Units
                  Up to five ETFs with an Outperform Smart Score that hold BMRN. The ETFs are listed according to market value of BMRN within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Alnylam Pharma

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis